- Home
- FPI vs KROS Comparison
FPI vs KROS Comparison
Compare FPI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPI
- KROS
- Stock Information
- Founded
- FPI 2013
- KROS 2015
- Country
- FPI United States
- KROS United States
- Employees
- FPI N/A
- KROS N/A
- Industry
- FPI Real Estate Investment Trusts
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- FPI Real Estate
- KROS Health Care
- Exchange
- FPI Nasdaq
- KROS Nasdaq
- Market Cap
- FPI 607.9M
- KROS 589.8M
- IPO Year
- FPI 2014
- KROS 2020
- Fundamental
- Price
- FPI $11.42
- KROS $12.02
- Analyst Decision
- FPI
- KROS Buy
- Analyst Count
- FPI 0
- KROS 11
- Target Price
- FPI N/A
- KROS $45.33
- AVG Volume (30 Days)
- FPI 312.0K
- KROS 2.0M
- Earning Date
- FPI 02-26-2025
- KROS 02-26-2025
- Dividend Yield
- FPI 2.11%
- KROS N/A
- EPS Growth
- FPI N/A
- KROS N/A
- EPS
- FPI 0.32
- KROS N/A
- Revenue
- FPI $58,465,000.00
- KROS $651,000.00
- Revenue This Year
- FPI N/A
- KROS $303.27
- Revenue Next Year
- FPI N/A
- KROS N/A
- P/E Ratio
- FPI $35.43
- KROS N/A
- Revenue Growth
- FPI 1.30
- KROS 8037.50
- 52 Week Low
- FPI $9.70
- KROS $9.78
- 52 Week High
- FPI $12.85
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- FPI 42.29
- KROS 25.14
- Support Level
- FPI $11.37
- KROS $10.95
- Resistance Level
- FPI $11.90
- KROS $11.63
- Average True Range (ATR)
- FPI 0.24
- KROS 0.88
- MACD
- FPI -0.00
- KROS 1.25
- Stochastic Oscillator
- FPI 24.84
- KROS 32.42
About FPI Farmland Partners Inc.
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, citrus, blueberries, and vegetables. The company generates its revenues through the rent it receives from its tenants.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.